BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 26802148)

  • 1. Breakthrough therapies in B-cell non-Hodgkin lymphoma.
    Cheah CY; Fowler NH; Wang ML
    Ann Oncol; 2016 May; 27(5):778-87. PubMed ID: 26802148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next Generation of Targeted Molecules for Non-Hodgkin Lymphomas: Small-Molecule Inhibitors of Intracellular Targets and Signaling Pathways.
    Choe H; Ruan J
    Oncology (Williston Park); 2016 Sep; 30(9):847-58. PubMed ID: 27633417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting indolent non-Hodgkin lymphoma.
    Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
    Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current targeted therapies in lymphomas.
    Chung C
    Am J Health Syst Pharm; 2019 Oct; 76(22):1825-1834. PubMed ID: 31580408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Driving toward precision medicine for B cell lymphomas: Targeting the molecular pathogenesis at the gene level.
    Chung C
    J Oncol Pharm Pract; 2020 Jun; 26(4):943-966. PubMed ID: 31964218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting BCL-2 in B-cell lymphomas.
    Davids MS
    Blood; 2017 Aug; 130(9):1081-1088. PubMed ID: 28724540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapies for B-cell non-Hodgkin lymphoma.
    Briones J
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1305-16. PubMed ID: 19761434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.
    Salihoglu A; Ar MC; Soysal T
    Expert Rev Hematol; 2015 Dec; 8(6):765-83. PubMed ID: 26413907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies.
    Huang J; Fairbrother W; Reed JC
    Expert Rev Hematol; 2015 Jun; 8(3):283-97. PubMed ID: 25912824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
    Bonavida B; Vega MI
    Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing novel strategies to target B-cell malignancies.
    Fowler N; Oki Y
    Am Soc Clin Oncol Educ Book; 2013; ():366-72. PubMed ID: 23714549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.
    Rosenthal A
    Curr Hematol Malig Rep; 2017 Jun; 12(3):207-216. PubMed ID: 28439761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular target therapy for non-Hodgkin lymphoma].
    Kato H; Kinoshita T
    Nihon Rinsho; 2014 Jun; 72(6):1104-12. PubMed ID: 25016812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drugs for the treatment of advanced-stage diffuse large cell lymphomas.
    O'Connor OA; Hamlin P
    Semin Hematol; 2006 Oct; 43(4):251-61. PubMed ID: 17027659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
    Kubuschok B; Trepel M
    Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
    Bhatt G; Maddocks K; Christian B
    Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New concepts in treatment approaches and prognostic factors in aggressive NHL.
    Shipp M
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):107-9. PubMed ID: 16728917
    [No Abstract]   [Full Text] [Related]  

  • 20. Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.
    Merli M; Ferrario A; Maffioli M; Arcaini L; Passamonti F
    Expert Opin Investig Drugs; 2015; 24(7):897-912. PubMed ID: 25900401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.